Diagnostics rightfully back in vogue given the importance of data in drug development, and hard to find a risk / reward more compelling than $XGN at sub-2.5x revs with the sector at 9-10x. That said, $BDSX also looks v interesting.
- this is the next area to read out for $MRNA
